Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine Given With Prevnar 13 in Healthy Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female infant born at \>36 weeks of gestation and aged 2 months (42 to 98 days) at the time of consent (the day of birth is considered day of life 1).~* Healthy infant determined by medical history, physical examination, and clinical judgment.~Exclusion Criteria:~* Previous vaccination with licensed or investigational pneumococcal vaccine.~* Prior receipt of routine pediatric vaccines, with the exception of hepatitis B vaccine.~* Previous receipt of \>1 dose of hepatitis B vaccine.~* Prior hepatitis B vaccine must have been administered at age \<30 days.~* Major known congenital malformation or serious chronic disorder.~* Receipt of blood/plasma products or immunoglobulins.

- Gender: ALL
- Minimum Age: 42 Days
- Maximum Age: 98 Days
- Healthy Volunteers: t

Study Arms:
- Group 1 - Coadministration (Type: EXPERIMENTAL): Multivalent pneumococcal conjugate vaccine coadministered with Prevnar 13
- Group 2 - Staggered Administration (Type: EXPERIMENTAL): Multivalent pneumococcal conjugate vaccine given 1 month after Prevnar 13
- Group 3 - Control with Supplemental Dose (Type: ACTIVE_COMPARATOR): Prevnar 13 with a single dose of multivalent pneumococcal conjugate vaccine

Based on this trial design, predict the completion outcome and termination type (if applicable).